- identity (MS)
- purity (HPLC)
- net content
- endotoxin
- sterility (USP <71>)
- heavy metals
GIP/GLP-1/glucagon triple agonist · GLP-1 · research compound
Retatrutide (Reta) for sale: compare suppliers, 10mg prices
For research use only. Price before shipping and tax. Affiliate link: it never affects grades or order.
Where to buy Reta (retatrutide) for research: Retatrutide 10mg vials cost from $94.99 ($9.50/mg) at LA Peptides, observed 14 Nov 2026, and 2 vendors have current prices for this package. Across 5 sizes in stock, prices run from $6.25/mg (48mg) to $10.50/mg (10mg). US-dollar list prices before shipping, tax and unverified codes. These are research-use package prices, not clinic or monthly prescription costs.
Investigational: phase 3 trial results are published, no regulator has approved retatrutide as of 5 Nov 2026, and Lilly plans a US submission in Q1 2027 (a plan, not a launch date).
ranked by use case · prices read in the last 7 days · no supplier pays for a place
Where to buy Retatrutide
2 suppliers have Retatrutide in stock at a price read in the last 7 days. PeptideTech names no single best supplier: the list is ranked by price per mg for 10mg, and the leader for each use case is marked.
- best valueLA Peptides$9.50/mg for 10mg · price read 14 Nov 2026
- best documentedAmerican Peptidesvendor grade 71/100 · from lab documents and records, never paid
- most sizes in stockAmerican Peptides4 sizes at a current price
| rank | supplier | package | price | per mg | vendor grade | sizes in stock | price read | supplier link |
|---|---|---|---|---|---|---|---|---|
| rank 1 | LA Peptides | 1 vial · 10mg labelled | $94.99 | $9.50/mg | 3 sizes | view offer, Retatrutide 10mg at LA Peptides, opens in a new tab | ||
| rank 2 | American Peptides | 1 vial · 10mg labelled | $105.00 | $10.50/mg | 4 sizes | view offer, Retatrutide 10mg at American Peptides, opens in a new tabcopies code TECH10 |
How it is ranked. Suppliers with 10mg in stock come first, cheapest price per mg first; a supplier without it follows with its cheapest current package. Best documented is the PeptideTech vendor grade (rubric v0.6), computed from lab documents, business records and service terms; no supplier can pay for a grade or a place, and the featured partner gets no extra place here. Most sizes counts the sizes in stock at a current price. Prices are listed prices before codes, shipping and tax; a price older than 7 days is left out. how supplier evidence is assessed
sorted by price · 10mg · prices before codes and shipping · checked 17 Nov 2026
Retatrutide 10mg offers
research market · not for human use
- identity (MS)
- purity (HPLC)
- net content
- endotoxin
- heavy metals
Prices are each vendor’s listed price before shipping, unless a verified code is marked as included. Some outbound links are affiliate links and PeptideTech keeps a fee from sellers on checkout orders; neither affects grades or scores, or order apart from the labelled featured partner. PeptideTech does not test products. Certificates of analysis are the seller’s or the lab’s documents, attributed to them, and PeptideTech does not verify them unless a specific record says so. Report a seller
one exact package · 1 vial · 10mg labelled · US dollars before shipping and tax
Retatrutide 10mg supplier comparison
Retatrutide price per mg by supplier
| supplier | package | price (USD) | per mg | status | observed | code terms | lot certificate |
|---|---|---|---|---|---|---|---|
| LA Peptides evidence profile | 1 vial · 10mg labelled | $94.99 | $9.50/mg | current · in stock | 14 Nov 2026 | no code | Bioviridian Inc. · 5 Sep 2026 · lot 1518 |
| American Peptides evidence profile | 1 vial · 10mg labelled | $105.00 | $10.50/mg | current · in stock | 17 Nov 2026 | code TECH10 carried by our link; not deducted (discount unverified) | Bioviridian Inc. · 17 Aug 2026 · lot RETA10-0803 |
| Blank Peptides evidence profile | 1 vial · 10mg labelled | $105.00 | $10.50/mg | historical | 30 Sep 2026 | code PEPTECH carried by our link; not deducted (discount unverified) | Horizon Analytical · 22 Aug 2026 · lot DPS-7922284 |
- Package. Every row is a single vial (1 vial · 10mg labelled); multi-vial packs, kits and bundles are left off this comparison.
- Price scope. Each vendor’s listed item price in US dollars for the US market, before shipping and sales tax, which its checkout sets. A code is deducted only when its discount was verified in a cart. These are research-use package prices, not clinic, prescription or monthly programme costs.
- Current or historical. A price is current when its source was read in the last seven days; historical rows are older listings, kept with their date and left out of the lowest price and the structured data.
How offers are selected
- Every row is one exact package: 10mg, one form, US market, US-dollar price as the vendor lists it.
- Vials, multi-vial packs, bundles, pens, sprays and blends stay in separate comparisons; kits and subscriptions are left out.
- Offers are ranked by displayed price; a code is included only when its discounted price was verified in a cart. A referral code is not a confirmed discount.
- A price is current when its source was read in the last 7 days; older listings stay visible as historical and are excluded from the lowest price. Read each offer’s source date, stock, currency and market.
- A catalogue name or alias (a vendor code name) is the seller’s claim: check it against the product specification and the lot report.
- Grades come from lab documents, business records and service terms, scored the same way for every vendor; no vendor can pay for a grade or rank.
Grading rubric, sources and corrections: how supplier evidence is assessed.
every size · lowest current in-stock price · US dollars before shipping
Retatrutide price by size
| size | package | from | per mg | cheapest vendor | observed | availability |
|---|---|---|---|---|---|---|
| Retatrutide 10mg price this page | 1 vial · 10mg labelled | $94.99 | $9.50/mg | LA Peptides | 14 Nov 2026 | 2 in stock |
| Retatrutide 15mg price | 1 vial · 15mg labelled | — | — | — | — | historical · last $119.00 at Blank Peptides, 30 Sep 2026 |
| Retatrutide 20mg price | 1 vial · 20mg labelled | $169.99 | $8.50/mg | LA Peptides | 14 Nov 2026 | 2 in stock |
| Retatrutide 30mg price | 1 vial · 30mg labelled | $229.99 | $7.67/mg | LA Peptides | 14 Nov 2026 | 1 in stock |
| Retatrutide 48mg price | 1 vial · 48mg labelled | $300.00 | $6.25/mg | American Peptides | 17 Nov 2026 | 1 in stock |
| Retatrutide 60mg price | 1 vial · 60mg labelled | $400.00 | $6.67/mg | American Peptides | 17 Nov 2026 | 1 in stock |
10mg is compared on this page; every other size opens its own supplier comparison. Prices exclude shipping and tax.
in-stock offers · every size · per mg before codes and shipping
what it costs
Dated observations, daily medians and CSV or JSON downloads for this package: Retatrutide price history and methodology.
from the evidence tiers
evidence
phase 2–3 human trials
basis: phase 2 RCTs · NEJM 2023, Lancet 2023
- cell studies
- animal studies
- small human studies
- phase 2 trial
- phase 3 trial
- approved somewhere
9 lot certificates matched to Retatrutide packages · newest first
lab results
- LA Peptideslot 1918 · Bioviridian Inc. · 20 Oct 2026identity (MS)net contentpurity (HPLC)endotoxinheavy metalssterility (USP <71>)

- LA Peptideslot 1518 · Bioviridian Inc. · 9 Sep 2026identity (MS)net contentpurity (HPLC)endotoxinheavy metalssterility (USP <71>)

- LA Peptideslot 1518 · Bioviridian Inc. · 5 Sep 2026identity (MS)net contentpurity (HPLC)endotoxinheavy metalssterility (USP <71>)

- Blank Peptideslot DPS-7922284 · Horizon Analytical · 22 Aug 2026identity (MS)purity (HPLC)net contentappearance

- American Peptideslot RETA10-0803 · Bioviridian Inc. · 17 Aug 2026identity (MS)net contentpurity (HPLC)endotoxinheavy metals

- American Peptideslot RETA20-0803 · Bioviridian Inc. · 17 Aug 2026identity (MS)net contentpurity (HPLC)endotoxinheavy metals

- American Peptideslot RETA30-0803 · Bioviridian Inc. · 17 Aug 2026identity (MS)net contentpurity (HPLC)endotoxinheavy metals

- American Peptideslot RETA60-0803 · Bioviridian Inc. · 17 Aug 2026identity (MS)net contentpurity (HPLC)endotoxinheavy metals

- American Peptideslot RETA48-0616 · Bioviridian Inc. · 25 Jun 2026identity (MS)net contentpurity (HPLC)endotoxinheavy metals

Vendor-published certificates matched to the exact package. PeptideTech has not authenticated the samples; tests are what each document prints. How to check a certificate, and the former storefront’s archived reports (none for Retatrutide), are in the COA directory and historical certificate library.
newest Retatrutide lot certificate at each vendor
assays per lot
- LA Peptides6×identity (mass spec)net contentpurity (HPLC)endotoxinheavy metalssterility (USP 71)lot COA10584 · 20 Oct 2026 · read from library
- American Peptides5×endotoxinheavy metalsidentity (mass spec)net contentpurity (HPLC)lot RETA10-0803 · 17 Aug 2026 · audit
- Amino USA4×appearanceidentity (mass spec)net contentpurity (HPLC)lot 26RETA5-0007 · 15 Apr 2026 · audit
- Blank Peptides4×appearanceidentity (mass spec)net contentpurity (HPLC)lot DPS-7922284 · 22 Aug 2026 · audit
More assays means more is documented, not that the product measured better. Shown beside grades; the vendor grade scores six core tests.
what it is · what is known
overview
Retatrutide is a peptide studied as a triple GIP, GLP-1 and glucagon receptor agonist. A randomized phase 2 obesity trial enrolled 338 adults and followed treatment for 48 weeks. The study reported weight reductions and adverse events, including gastrointestinal events and changes in heart rate. Its results apply to the investigational formulation and selected trial population; they do not establish the identity, quality or safety of research-vendor material.
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England), 2026
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology, 2025
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine, 2024
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine, 2023 — Randomized, double-blind, placebo-controlled phase 2 study in 338 adults with obesity. Reports 48-week weight outcomes and adverse events; vendor research products were not evaluated.
research-use status
is Retatrutide legal?
This page compares research-labelled listings for Retatrutide. A listing or a United States price does not establish authorization for human use or permission to import, possess or supply a product in a particular jurisdiction. Consult the cited regulatory sources and the rules for the actual product and destination. PeptideTech does not sell products or provide medical advice.
Regulator and trial status, with the date each was checked: Retatrutide approval and availability updates.
research context
Retatrutide storage and handling
Follow the manufacturer’s current product- and batch-specific storage instructions and safety data sheet for Retatrutide. The catalogue does not verify temperature stability, sterility or a preparation method. Do not transfer handling instructions between different forms, concentrations or suppliers.
Vial mass, diluent volume and concentration arithmetic for a laboratory: the Retatrutide concentration calculator.
side by side
compare
also in GLP-1
similar compounds
- Cagrilintideevidence B · from $99.99
- Liraglutideevidence A · from $51.00
- Mazdutideevidence B
- Retatrutide / Cagrilintideevidence B
- Semaglutideevidence A · from $89.99
- Survodutideevidence B
how this page is built
independence
Grades are computed from lab data and public records; no vendor can pay for a grade or a ranking. Featured placements are labelled and sit outside the rankings; in them the featured partner holds the place its price or score earns. how we make money
lowest 10mg: LA Peptides $94.99, Retatrutide 10mg at LA Peptides, opens in a new tab
short answers
Retatrutide questions
How much does Retatrutide cost?
Where is the cheapest place to buy Retatrutide?
Where can I compare current Retatrutide supplier offers?
Which Retatrutide supplier is best for a given package?
Is the Retatrutide 10mg price for one vial or several?
Why do 10mg and 60mg Retatrutide prices differ?
How much does each Retatrutide size cost?
What sizes of Retatrutide are available?
Are the Retatrutide prices and discount codes current?
Which Retatrutide coupon codes work?
What does a Retatrutide COA show?
Is Retatrutide FDA approved?
Has Retatrutide been tested in clinical trials?
Is Retatrutide legal to buy?
Is the Retatrutide price a clinic or monthly cost?
Can you purchase retatrutide?
Do you need a prescription for retatrutide?
Is retatrutide the same as Ozempic?
What is the price of retatrutide 10mg in the USA?
Retatrutide price history
Actual source observations from the last 14 days, shown separately by supplier, package and currency. Missing days are not filled in. The first refresh can preserve an earlier recorded price; it does not establish a daily price history.
| Observed (UTC) | Supplier | Package | Price | Stock |
|---|---|---|---|---|
| 2026-11-17 07:50 | American Peptides | 10mg · Vial | $105.00 | In stock |
| 2026-11-16 08:02 | American Peptides | 10mg · Vial | $105.00 | In stock |
| 2026-11-15 07:50 | American Peptides | 10mg · Vial | $105.00 | In stock |
| 2026-11-14 07:51 | LA Peptides | 10mg · Vial | $94.99 | In stock |
| 2026-11-14 07:49 | American Peptides | 10mg · Vial | $105.00 | In stock |
| 2026-11-13 07:52 | LA Peptides | 10mg · Vial | $94.99 | In stock |
| 2026-11-13 07:50 | American Peptides | 10mg · Vial | $105.00 | In stock |
| 2026-11-12 07:50 | American Peptides | 10mg · Vial | $105.00 | In stock |
| 2026-11-11 07:49 | American Peptides | 10mg · Vial | $105.00 | In stock |
| 2026-11-10 07:50 | American Peptides | 10mg · Vial | $105.00 | In stock |
| 2026-11-09 07:50 | American Peptides | 10mg · Vial | $105.00 | In stock |
| 2026-11-08 07:49 | American Peptides | 10mg · Vial | $105.00 | In stock |
Research reference
Selected sources reviewed
Retatrutide, also identified as LY3437943, is an investigational agonist at GIP, GLP-1 and glucagon receptors. A peer-reviewed phase 2 trial and a later sponsor-described phase 3 program are different levels of source evidence.[1][2]
Identity checks
“Triple agonist” names the three receptor targets; it does not identify a separate “GLP-3” receptor or authenticate a product sold under that nickname.[1][2]
Published phase 2 evidence; phase 3 sponsor updates
The published randomized phase 2 trial enrolled 338 adults. Lilly’s current information describes an investigational phase 3 development program. Sponsor updates are identified as sponsor information, not substituted for a peer-reviewed paper or regulatory approval.[1][2]
Regulatory context
Drugs@FDA lists no NDA, BLA or ANDA with retatrutide as an active ingredient (names searched: RETATRUTIDE, LY3437943; checked October 7, 2026). Research-labelled Retatrutide listings are not FDA-approved drugs.
Sources: Drugs@FDA active-ingredient search: RETATRUTIDE, LY3437943 · checked
FDA states that retatrutide is not a component of an FDA-approved drug. Lilly describes it as investigational. This review does not infer regulatory status for every country.[3][2]
Supporting sources
- Retatrutide for obesity: a randomized phase 2 trialNew England Journal of Medicine · PubMed record · checked
- What to know about retatrutideEli Lilly and Company · trial sponsor · checked
- FDA concerns with unapproved GLP-1 drugs used for weight lossU.S. Food and Drug Administration · checked
Research searches — not supporting citations
Search results may include unrelated records. A search link does not establish that a matching study exists.
These selected sources describe named substances and studied formulations. They do not authenticate a supplier, a certificate of analysis or the contents of a particular lot, and do not provide instructions for use. “Healing” and other catalogue categories are navigation labels, not evidence of efficacy or treatment recommendations.
Retatrutide research and reading
Read the evidence, identity checks and limitations alongside the catalogue. Research findings do not verify a vendor’s product or establish suitability for personal use.
Retatrutide Storage: Powder, Solutions & Evidence Limits
What each retatrutide supplier actually states about storing the powder and a solution, what stability evidence exists, and why no shelf life can be taken from other peptides.
Updated Nov 5, 2026Retatrutide Approval Status, Availability & Trial Updates
Is retatrutide FDA approved? A dated status box, the approval-versus-trial timeline, a registry table and the phase 3 papers published so far, with unknowns stated plainly.
Updated Nov 5, 2026Retatrutide, Tirzepatide & Semaglutide: Evidence Compared
A three-way matrix of receptor targets, authorization status and trials, plus which pairs have head-to-head evidence and why separate trial results cannot be ranked.
Updated Nov 5, 2026Save Retatrutide
Bookmark this product in your browser. To keep a particular supplier, size and form, use “Save offer” beside a price. Neither feature sends alerts or creates a subscription.